Innovative therapy that ‘tricks’ and destroys cancer cells advance to clinical trial

Results from pre-clinical research show iron-like compound hold promise for treating patients with glioblastoma, an aggressive brain cancer

CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA

Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein

Mankind Pharma and Innovent Biologics join forces for cancer care with Sintilimab

Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India

Lonza extends collaboration with global biopharmaceutical partner for commercial-scale manufacture of ADCs

Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC

Shilpa Medicare’s CDMO customer gets fast-track designation for its investigational drug candidate

GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally

Aster implements India’s first IOeRT for cancer care

To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients

Boehringer Ingelheim acquires Nerio Therapeutics for US$ 1.3bn

Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio

Zydus and Dr. Reddy's announce licensing agreement for co?marketing of Pertuzumab biosimilar

AbbVie announces positive results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine for high FR? expressing platinum-sensitive ovarian cancer

PICCOLO trial met its primary endpoint of objective response rate (ORR)

AstraZeneca plans $1.5 billion ADCs manufacturing facility in Singapore

Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs